Magnolia Capital Advisors LLC Buys 74 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Magnolia Capital Advisors LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.9% during the fourth quarter, Holdings Channel reports. The fund owned 2,625 shares of the medical research company’s stock after acquiring an additional 74 shares during the quarter. Magnolia Capital Advisors LLC’s holdings in IQVIA were worth $516,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in IQV. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter worth approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the 3rd quarter worth approximately $28,000. Synergy Asset Management LLC bought a new position in IQVIA in the 4th quarter worth approximately $33,000. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Finally, Assetmark Inc. grew its holdings in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of NYSE IQV opened at $201.34 on Monday. The stock has a 50 day moving average price of $200.41 and a 200 day moving average price of $220.39. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market capitalization of $36.54 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48.

Analysts Set New Price Targets

A number of research analysts have issued reports on IQV shares. Bank of America decreased their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. BTIG Research decreased their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Barclays decreased their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $255.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.